Galectin Therapeutics, Inc. (GALT)
4.12
-0.02
(-0.48%)
USD |
NASDAQ |
Sep 09, 14:01
Galectin Therapeutics Debt to Equity Ratio : -1.007 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.007 |
| March 31, 2026 | -1.042 |
| December 31, 2025 | -1.060 |
| September 30, 2025 | -0.9897 |
| June 30, 2025 | -1.028 |
| March 31, 2025 | -0.9619 |
| December 31, 2024 | -1.031 |
| September 30, 2024 | -1.131 |
| June 30, 2024 | -1.138 |
| March 31, 2024 | -1.161 |
| December 31, 2023 | -1.192 |
| September 30, 2023 | -1.203 |
| June 30, 2023 | -1.181 |
| March 31, 2023 | -1.172 |
| December 31, 2022 | -1.240 |
| September 30, 2022 | -1.333 |
| June 30, 2022 | -1.946 |
| March 31, 2022 | -4.729 |
| December 31, 2021 | 11.11 |
| September 30, 2021 | 2.089 |
| June 30, 2021 | 0.5652 |
| March 31, 2021 | 0.0023 |
| December 31, 2020 | 0.0021 |
| September 30, 2020 | 0.002 |
| June 30, 2020 | 0.0019 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0019 |
| December 31, 2019 | 0.002 |
| September 30, 2019 | 0.002 |
| June 30, 2019 | 0.0021 |
| March 31, 2019 | 0.0168 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 14.83M |
| Total Liabilities (Quarterly) | 151.68M |
| Shareholders Equity (Quarterly) | -136.85M |
| Current Ratio | 0.0967 |
| Net Debt Paydown Yield | -1.94% |